




版權(quán)說(shuō)明:本文檔由用戶(hù)提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
THECHILDHOODLEUKEMIA
THECHILDHOODLEUKEMIA1LeukemiaLeukemiaisadiseasecharacterizedbyproliferationofimmaturewhitecellsandisthemostcommonmalignancyofchildhood.Acuteleukemiasaccountforthemajority(97%)ofcases.LeukemiaLeukemiaisadisease2LeukemiaTheleukemiasareclassifiedaccordingtothewhitebloodcelllineinvolved:
Acutelymphocyticleukemia(ALL)-----cellsoflymphoidlineage
Acutenon-lymphocyticleukemia(ANLL)-----cellsofgranulocyticormonocyticlineage.LeukemiaTheleukemiasar3Acutelymphocyticleukemia
ALLaccountfor80%ofchildhoodleukemiaandhasapeakinincidencebetweenage3and6years.Itisslightlymorecommoninboysthangirls.Acutelymphocyticleukemia
ALL4AcutelymphocyticleukemiaChildrenwithDownsyndrome,Fanconianemia,andataxiatelangiectasiaareatparticularriskofALL.Siblings,especiallytwins,ofchildrenwithleukemiaareapproximatelytwiceaslikelytohaveleukemiathanisthegeneralpopulation..AcutelymphocyticleukemiaChil5AcutelymphocyticleukemiaSomecasesofchildhoodALLmayrelatetohereditaryoracquiredmutationinthep53gene.Takenintotal,however,thesepredisposingcircumstancesorrelationshipsaccountforonlyasmallpropotionofcasesAcutelymphocyticleukemiaSome6ClinicalfeaturesInmostchildrenwithALL,thereisanacuteonsetofsymptomsandsignsarsingfrominfiltrationofthebonemarroworotherorganswithleukemicblastcells.Mostwillhaveoneormoreofthefollowing:ClinicalfeaturesInmostchild7Clinicalfeatures
“4Ps”
Pallor----anemia.Pyrexia----concomitantinfectionorthedeseaseitself.Purpura----thrombocytopeniaPain----Bonepain(pelvis,vertebralbodies,legs),duetoexpansionofmarrowcavity.
Abdominalpain,duetoliverandspleendistension.Clinicalfeatures
“4Ps”8ExpansionofmarrowcavityExpansionofmarrowcavity9ClinicalfeaturesasymtomaticlymphadenopathyandhepatosplenomegalytheCNS,testesandthekidneys----themostcommonlyaffectedextramedullarysites
Infection
----duetoneutropeniaClinicalfeaturesasymtomaticl10ClinicalfeatureHepatosplenomegalyreticuloendotheelialcellinfiltration.ClinicalfeatureHepatosplenome11白血病英文課件12Investigations
Peripheralbloodinvestigationsreveal:Anemia----normocytic,normochromic.Thombocytopenia.Neutropenia----totalWBCmaybelow,normal,orhigh.Blastcells.Investigations
Peripheralbloo13InvestigationsBonemarrowexaminationreveals:Replacementofnormalelementsbyleukemiccells.Adiagnosisofleukemiashouldalwaysbeconfirmedbybonemarrowaspiration.InvestigationsBonemarrowexam14MorphologiesandhistochemicalclassificationUnderlightmicroscope,thesystemdevelopedbyFABdivideslymphablastsinto3categories:L1:small,scantycytoplasmandinconspicuousnucleoli.(85%ofcases)L2:generallylarger,moreprominentnucleoliandabundantcytoplasm.L3
:large,deepcytoplasmicbasophilicandprominentcytoplasmicvacuolation,identicaltothecellsofBurkittlymphoma.(1-2%)Morphologiesandhistochemical15ALL-L1ALL-L2ALL-L3ALL-L1ALL-L2ALL-L316DifferentialdiagnosisInfectiousmononcleosisHistiocytosisXHypoplasticandaplasticanemiaJuvenilerheumatoidarthritisITP
DifferentialdiagnosisInfectio17TreatmentSurportivetherapySpecifictherapyPreventionofCNSLTreatmentofTLTransplantationofhemopoieticstemcellTreatmentSurportivetherapy18SpecifictreatmentInduction
(VDLP/CODPL)Consolidation(CAT/VM26+A)Prevetionofextramedullaryleukemia(HDMTX)Maintenance(6-MP+MTX)IntensifySpecifictreatmentInduction(V19SurportivetreatmentTreatmentofinfection.TransfusedbloodandplateletG-CSFandGM-CSFPrevetionoftumorlysissyndromeAlkalinizationofurineHydrationAllopurinolTheotherSurportivetreatmentTreatment20PrevetionofextramedullaryleukemiaintrathecalMTX,Ara-CandDXMHDMTX+CFPrevetionofextramedullaryle21TreatmentofCNSLintrathecalMTX,Ara-CandDXM(三聯(lián)鞘內(nèi)注射法)HDMTX+CF(大劑量甲氨蝶呤-四氫葉酸鈣)cranialirradiation(顱腦放射治療)TreatmentofCNSLintrathecalM22Induction4weeksofcombinationchemotherapy:VDPL/CODPLDNR(柔紅霉素)L-asparaginase(左旋門(mén)冬酰氨)Vincristine(長(zhǎng)春新堿)Prednisolone(潑尼松)CODPL
Induction4weeksofcombinatio23Maintenance
chemotherapycontinuesfor2yearsfromdiagnosis:6-MPor6-TG(硫鳥(niǎo)嘌呤)+MTXFormerinductiontherapyshouldbecarriedonPeriodicallyMaintenancechemotherapyconti24Consolidationcontinuedsystemictherapywithblocksof“intensification”therapyforselectedpatients.VM-26+Ara-c/VDP/VDPLCAM(T)CTX(甲氨蝶呤)Ara-c(阿糖胞苷)6MP(巰嘌呤)(6-TG)
Consolidationcontinuedsystemi25PrognosisThechildrencangetmuchbetterprognosisthanthetheadult.Their5-yearsurvivalrateis70-80%,whiletheircounterpartis20-30%.ANLL:5-yearsurvivalrateis40-50%PrognosisThechildrencanget26白血病細(xì)胞的遺傳學(xué)特征染色體數(shù)目50的超二倍體急淋細(xì)胞97%以上含有3~4條21號(hào)染色體,21號(hào)染色體上有編碼還原型四氫葉酸轉(zhuǎn)運(yùn)蛋白的拷貝基因,這種轉(zhuǎn)運(yùn)蛋白的高表達(dá)導(dǎo)致甲氨蝶呤的活性代謝產(chǎn)物多聚谷氨酰甲氨蝶呤在細(xì)胞內(nèi)的高度累積,因此超二倍體急淋細(xì)胞對(duì)基于甲氨蝶呤的化療異常敏感,這類(lèi)病人的預(yù)后非常好,5年EFS為75%~90%。白血病細(xì)胞的遺傳學(xué)特征染色體數(shù)目50的超二27白血病細(xì)胞的遺傳學(xué)特征美國(guó)COG組研究顯示4、10和17三體也是獨(dú)立的預(yù)后良好指標(biāo),這類(lèi)病人7年EFS90%,機(jī)理尚不清楚。白血病細(xì)胞的遺傳學(xué)特征美國(guó)COG組研究顯示428白血病細(xì)胞的遺傳學(xué)特征t(12;21)(p13;q22)易位形成的融合基因TEL/AML1見(jiàn)于25%急淋患兒。研究表明這類(lèi)白血病細(xì)胞對(duì)L-ASP高度敏感。stJude兒童研究醫(yī)院用含有L-ASP的強(qiáng)化療治療t(12;21)陽(yáng)性的ALL患兒獲得較好效果。一般認(rèn)為t(12;21)陽(yáng)性患兒首次完全緩解期長(zhǎng)且早期復(fù)發(fā)率低,但部分患兒晚期復(fù)發(fā),復(fù)發(fā)后對(duì)化療依然敏感,易獲二次緩解。白血病細(xì)胞的遺傳學(xué)特征t(12;21)(p1329白血病細(xì)胞的遺傳學(xué)特征
t(1;19)(q23;q13)易位形成的E2A/PBX1融合基因多見(jiàn)于胞漿重鏈陽(yáng)性的前B急淋。過(guò)去認(rèn)為t(1;19)陽(yáng)性急淋患兒發(fā)病時(shí)常伴有高白細(xì)胞數(shù)、高LDH及高CNS白血病發(fā)病率,預(yù)后不佳。但近年來(lái)強(qiáng)烈化療已使其成為兒童急淋中預(yù)后最良好型之一,這部分患兒的5年EFS接近90%。白血病細(xì)胞的遺傳學(xué)特征t(1;19)(q2330白血病細(xì)胞的遺傳學(xué)特征位于11q23的MLL基因可與30多種基因發(fā)生易位,統(tǒng)稱(chēng)MLL基因重排,見(jiàn)于6%的急淋患兒,其中最常見(jiàn)的為t(4;11)(q21;q23)易位形成的融合基因MLL/AF4,絕大多數(shù)嬰兒白血病表達(dá)該融合基因。最近一個(gè)大宗病例統(tǒng)計(jì)顯示任何MLL基因重排的ALL患兒預(yù)后都不好,長(zhǎng)期EFS只有20%~25%,尤其MLL基因重排的嬰兒比1歲以上患兒預(yù)后更差。t(4;11)陽(yáng)性嬰兒白血病細(xì)胞對(duì)阿糖胞苷相對(duì)敏感。白血病細(xì)胞的遺傳學(xué)特征位于11q23的MLL31白血病細(xì)胞的遺傳學(xué)特征
t(9;22)(q34;q11)易位形成的融合基因BCR/ABL見(jiàn)于3%~5%的兒童急淋,為預(yù)后最差的一類(lèi),尤其初診白細(xì)胞≥50109/L、發(fā)病年齡≥10歲或強(qiáng)的松反應(yīng)不良的患兒建議第一次緩解后即行異基因造血干細(xì)胞移植,以減少?gòu)?fù)發(fā),提高總體生存率。
白血病細(xì)胞的遺傳學(xué)特征t(9;22)(q332THECHILDHOODLEUKEMIA
THECHILDHOODLEUKEMIA33LeukemiaLeukemiaisadiseasecharacterizedbyproliferationofimmaturewhitecellsandisthemostcommonmalignancyofchildhood.Acuteleukemiasaccountforthemajority(97%)ofcases.LeukemiaLeukemiaisadisease34LeukemiaTheleukemiasareclassifiedaccordingtothewhitebloodcelllineinvolved:
Acutelymphocyticleukemia(ALL)-----cellsoflymphoidlineage
Acutenon-lymphocyticleukemia(ANLL)-----cellsofgranulocyticormonocyticlineage.LeukemiaTheleukemiasar35Acutelymphocyticleukemia
ALLaccountfor80%ofchildhoodleukemiaandhasapeakinincidencebetweenage3and6years.Itisslightlymorecommoninboysthangirls.Acutelymphocyticleukemia
ALL36AcutelymphocyticleukemiaChildrenwithDownsyndrome,Fanconianemia,andataxiatelangiectasiaareatparticularriskofALL.Siblings,especiallytwins,ofchildrenwithleukemiaareapproximatelytwiceaslikelytohaveleukemiathanisthegeneralpopulation..AcutelymphocyticleukemiaChil37AcutelymphocyticleukemiaSomecasesofchildhoodALLmayrelatetohereditaryoracquiredmutationinthep53gene.Takenintotal,however,thesepredisposingcircumstancesorrelationshipsaccountforonlyasmallpropotionofcasesAcutelymphocyticleukemiaSome38ClinicalfeaturesInmostchildrenwithALL,thereisanacuteonsetofsymptomsandsignsarsingfrominfiltrationofthebonemarroworotherorganswithleukemicblastcells.Mostwillhaveoneormoreofthefollowing:ClinicalfeaturesInmostchild39Clinicalfeatures
“4Ps”
Pallor----anemia.Pyrexia----concomitantinfectionorthedeseaseitself.Purpura----thrombocytopeniaPain----Bonepain(pelvis,vertebralbodies,legs),duetoexpansionofmarrowcavity.
Abdominalpain,duetoliverandspleendistension.Clinicalfeatures
“4Ps”40ExpansionofmarrowcavityExpansionofmarrowcavity41ClinicalfeaturesasymtomaticlymphadenopathyandhepatosplenomegalytheCNS,testesandthekidneys----themostcommonlyaffectedextramedullarysites
Infection
----duetoneutropeniaClinicalfeaturesasymtomaticl42ClinicalfeatureHepatosplenomegalyreticuloendotheelialcellinfiltration.ClinicalfeatureHepatosplenome43白血病英文課件44Investigations
Peripheralbloodinvestigationsreveal:Anemia----normocytic,normochromic.Thombocytopenia.Neutropenia----totalWBCmaybelow,normal,orhigh.Blastcells.Investigations
Peripheralbloo45InvestigationsBonemarrowexaminationreveals:Replacementofnormalelementsbyleukemiccells.Adiagnosisofleukemiashouldalwaysbeconfirmedbybonemarrowaspiration.InvestigationsBonemarrowexam46MorphologiesandhistochemicalclassificationUnderlightmicroscope,thesystemdevelopedbyFABdivideslymphablastsinto3categories:L1:small,scantycytoplasmandinconspicuousnucleoli.(85%ofcases)L2:generallylarger,moreprominentnucleoliandabundantcytoplasm.L3
:large,deepcytoplasmicbasophilicandprominentcytoplasmicvacuolation,identicaltothecellsofBurkittlymphoma.(1-2%)Morphologiesandhistochemical47ALL-L1ALL-L2ALL-L3ALL-L1ALL-L2ALL-L348DifferentialdiagnosisInfectiousmononcleosisHistiocytosisXHypoplasticandaplasticanemiaJuvenilerheumatoidarthritisITP
DifferentialdiagnosisInfectio49TreatmentSurportivetherapySpecifictherapyPreventionofCNSLTreatmentofTLTransplantationofhemopoieticstemcellTreatmentSurportivetherapy50SpecifictreatmentInduction
(VDLP/CODPL)Consolidation(CAT/VM26+A)Prevetionofextramedullaryleukemia(HDMTX)Maintenance(6-MP+MTX)IntensifySpecifictreatmentInduction(V51SurportivetreatmentTreatmentofinfection.TransfusedbloodandplateletG-CSFandGM-CSFPrevetionoftumorlysissyndromeAlkalinizationofurineHydrationAllopurinolTheotherSurportivetreatmentTreatment52PrevetionofextramedullaryleukemiaintrathecalMTX,Ara-CandDXMHDMTX+CFPrevetionofextramedullaryle53TreatmentofCNSLintrathecalMTX,Ara-CandDXM(三聯(lián)鞘內(nèi)注射法)HDMTX+CF(大劑量甲氨蝶呤-四氫葉酸鈣)cranialirradiation(顱腦放射治療)TreatmentofCNSLintrathecalM54Induction4weeksofcombinationchemotherapy:VDPL/CODPLDNR(柔紅霉素)L-asparaginase(左旋門(mén)冬酰氨)Vincristine(長(zhǎng)春新堿)Prednisolone(潑尼松)CODPL
Induction4weeksofcombinatio55Maintenance
chemotherapycontinuesfor2yearsfromdiagnosis:6-MPor6-TG(硫鳥(niǎo)嘌呤)+MTXFormerinductiontherapyshouldbecarriedonPeriodicallyMaintenancechemotherapyconti56Consolidationcontinuedsystemictherapywithblocksof“intensification”therapyforselectedpatients.VM-26+Ara-c/VDP/VDPLCAM(T)CTX(甲氨蝶呤)Ara-c(阿糖胞苷)6MP(巰嘌呤)(6-TG)
Consolidationcontinuedsystemi57PrognosisThechildrencangetmuchbetterprognosisthanthetheadult.Their5-yearsurvivalrateis70-80%,whiletheircounterpartis20-30%.ANLL:5-yearsurvivalrateis40-50%PrognosisThechildrencanget58白血病細(xì)胞的遺傳學(xué)特征染色體數(shù)目50的超
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶(hù)所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶(hù)上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶(hù)上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶(hù)因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 小學(xué)英語(yǔ)名詞變復(fù)數(shù)知識(shí)總結(jié)練習(xí)
- 影視廣告設(shè)計(jì)的敘事技巧研究試題及答案
- 社會(huì)媒體對(duì)設(shè)計(jì)傳播的影響試題及答案
- 助理廣告師考試案例分享與分析試題及答案
- 梨園醫(yī)院筆試題目及答案
- 如何在廣告設(shè)計(jì)中實(shí)施反饋循環(huán)機(jī)制試題及答案
- 2024年紡織品檢驗(yàn)員考試考生分享經(jīng)驗(yàn)試題及答案
- 2024年商業(yè)美術(shù)設(shè)計(jì)師創(chuàng)意設(shè)計(jì)考題及答案
- 2024年設(shè)計(jì)師考試創(chuàng)作思路指導(dǎo)試題及答案
- 國(guó)畫(huà)審美測(cè)試題及答案
- 第二章中國(guó)體育產(chǎn)業(yè)的發(fā)展與現(xiàn)狀
- 靜脈炎的護(hù)理 課件
- DB3303T078-2024規(guī)模以上工業(yè)企業(yè)健康評(píng)價(jià)指標(biāo)體系
- 特種作業(yè)合同協(xié)議
- 社工證考試試題及答案
- 2025年云南專(zhuān)升本招生計(jì)劃
- 汽車(chē)營(yíng)銷(xiāo)專(zhuān)業(yè)畢業(yè)論文
- 2025年中國(guó)VOC治理市場(chǎng)深度評(píng)估研究報(bào)告
- 2025年寬帶網(wǎng)絡(luò)拓展合作協(xié)議書(shū)
- 教學(xué)主管競(jìng)聘培訓(xùn)機(jī)構(gòu)
- 【9語(yǔ)期末】黃山市歙縣2024-2025學(xué)年九年級(jí)上學(xué)期期末語(yǔ)文試題
評(píng)論
0/150
提交評(píng)論